Why Is Apollo Hospitals Share Price Falling? Key Reasons & Share Price Target 2026

Mon Apr 13 2026

Apollo Hospitals share price is down -24% from its 52-week high of Rs 7,650, trading at Rs 5,800 as of April 2026. At its 52-week low of Rs 5,200, the stock has already given up significant gains — and investors are asking the same question: is this a buying opportunity or a value trap?

The Apollo Hospitals share price falling is not random market noise. There are specific, identifiable reasons driving the decline — and this article examines each of them with real data, sector context, and the analyst consensus on what Apollo Hospitals is worth.

Click Here — Get Free Investment Predictions on Univest.

Table of Contents

Why Is Apollo Hospitals Share Price Falling? Key Reasons

Tap to Access Best Research Pieces on Univest.

Reason 1: High Valuation With Slowing ARPOB Growth

Apollo Hospitals at 72x P/E is one of the most expensive hospital stocks globally. The premium is justified by Apollo’s brand, clinical outcomes, digital health ecosystem (Apollo 24|7), and pharmacy business. However, ARPOB (Average Revenue Per Occupied Bed) growth has been slowing from 15-18% in FY23-24 to 8-10% in FY26 as the premium patient mix saturates.

Reason 2: Apollo 24|7 Digital Health — Losses Continue

Apollo’s digital health platform (Apollo 24|7) for teleconsultations, digital pharmacy, and diagnostics has been scaling but remains loss-making. The platform requires heavy investment in technology, marketing, and fulfilment. Until Apollo 24|7 turns EBITDA positive, it drags on consolidated profitability.

Reason 3: Competition from Max Healthcare, Manipal, Medanta

The hospital sector in India has become increasingly competitive. Max Healthcare (Delhi NCR), Manipal Hospitals (South India), and Medanta are all expanding capacity and competing for the same premium patient segments. This creates pricing pressure on procedures and potential ARPOB dilution.

Reason 4: Pharmacy Business — Regulatory and Competition Pressure

Apollo Pharmacy is India’s largest private pharmacy chain. The pharmacy retail market faces competition from PharmEasy, Tata 1mg, and Reliance Retail’s online pharmacy. The sector also faces regulatory scrutiny on prescribing and dispensing practices.

Reason 5: FII Selling — High Ownership Makes Stock Volatile

With 30.6% FII ownership and high absolute valuations, Apollo Hospitals is subject to disproportionate selling during global risk-off periods. The combination of high valuation and high FII ownership makes the stock volatile.

Apollo Hospitals Financial Snapshot

Parameter	Value
CMP	Rs 5,800
52-Week High	Rs 7,650
52-Week Low	Rs 5,200
Decline from Peak	-24%
Market Cap	Rs 83,000 Cr
P/E Ratio	72x
P/B Ratio	15x
Promoter Holding	29.3%
FII Holding	30.6%
DII Holding	22.4%
Sector	Hospitals / Healthcare Ecosystem

Track Apollo Hospitals live fundamentals and peer comparisons on the Univest Screener.

Download the Univest iOS App or Univest Android App for daily research updates.

Can Apollo Hospitals Recover? Future Outlook

Apollo Hospitals’ fundamental position as India’s most trusted premium hospital brand is unassailable. The current de-rating from Rs 7,650 to Rs 5,800 reflects valuation normalisation rather than fundamental deterioration. Apollo 24|7 profitability timeline and ARPOB recovery are the key re-rating catalysts. At Rs 5,800 and 72x P/E, the stock is attractive only for investors with a 2-3 year horizon. Recovery to Rs 6,800-7,500 requires consistent 15%+ revenue growth.

Apollo Hospitals Share Price Target 2026

Subscribe to Univest Pro for SEBI-registered analyst recommendations.

Short-Term Target (3-6 Months)

Short-term Apollo Hospitals share price target is Rs 5,500-6,400, based on current technical setup and near-term fundamental catalyst timeline. The 52-week low of Rs 5,200 is the key support level — a sustained break below this would be a significant bearish signal.

12-Month Analyst Consensus Target

Analyst consensus 12-month Apollo Hospitals share price target is Rs 6,800-7,500, implying meaningful upside from the current Rs 5,800. This assumes the key headwinds identified in this article begin to resolve.

Long-Term Target (FY28)

In a full recovery scenario, the Apollo Hospitals share price target for FY28 is Rs 9,000-10,500. This bull case requires the fundamental concerns in this article to show clear reversal over the next 4-6 quarters.

Frequently Asked Questions

Q1. Why is Apollo Hospitals share price falling in 2026?

Apollo Hospitals share price is falling primarily due to the reasons detailed in this article. The stock has declined -24% from its 52-week high of Rs 7,650 to the current Rs 5,800. Key factors include sector headwinds, earnings pressure, and broader market conditions. Review all factors before making any investment decision.

Q2. What is Apollo Hospitals share price target 2026?

Analyst consensus 12-month Apollo Hospitals share price target is Rs 6,800-7,500. Short-term target is Rs 5,500-6,400 and long-term FY28 target in a recovery scenario is Rs 9,000-10,500. These are analyst estimates and not guaranteed returns.

Q3. Should I buy Apollo Hospitals at current levels?

This article does not provide personalised investment advice. Apollo Hospitals is trading at Rs 5,800 with a 52-week range of Rs 5,200 to Rs 7,650. The risk-reward depends on your investment horizon and risk tolerance. Consult a SEBI-registered financial advisor before investing.

Q4. What is Apollo Hospitals’s market cap and P/E ratio?

Apollo Hospitals’s market capitalisation is Rs 83,000 Cr with a trailing P/E of 72x and price-to-book ratio of 15x. Promoter holding is 29.3%, FII 30.6%, DII 22.4%.

Q5. What can trigger recovery in Apollo Hospitals share price?

Recovery triggers for Apollo Hospitals include: resolution of the specific headwinds identified in this article, positive quarterly results showing reversal of stressed metrics, and broad market recovery. Monitor quarterly results and management commentary closely.

Disclaimer: For educational purposes only. Not investment advice. Consult a SEBI-registered financial advisor. Investments are subject to market risk.

For more analysis, visit Univest Blogs.